Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

62.70 -2.90 (-4.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 23, 2024

Via Benzinga

NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 23, 2024

Via Benzinga

VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 22, 2024

Via Benzinga

(CYTK) - Analyzing Cytokinetics's Short Interest ↗

May 01, 2024

Via Benzinga

$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today ↗

April 03, 2024

Via Benzinga

2 Incredible Growth Stocks to Buy Right Now ↗

March 20, 2024

These two biotech stocks could be big winners in the years ahead.

Via The Motley Fool

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22, 2024

From Royalty Pharma plc; Cytokinetics

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 17, 2024

Via Benzinga

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗

May 13, 2024

The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.

Via Investor's Business Daily

CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗

March 15, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in Cytokinetics ↗

February 28, 2024

Via Benzinga

Here's How Much $1000 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗

February 27, 2024

Via Benzinga

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

3 Biotech Stocks to Buy on the Dip: April 2024 ↗

April 26, 2024

With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip.

Via InvestorPlace

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Masters In Trading - Saturday, March 16 ↗

March 16, 2024

In this snippet from Friday's trading session, I review my various trades from the past week.

Via Talk Markets

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Here's How Much $1000 Invested In Cytokinetics 5 Years Ago Would Be Worth Today ↗

February 09, 2024

Via Benzinga

Here's How Much $100 Invested In Cytokinetics 5 Years Ago Would Be Worth Today ↗

February 02, 2024

Via Benzinga

Super Micro, Deckers To Join S&P 500 Index ↗

March 01, 2024

They'll replace Whirlpool and Zions Bancorp on March 18.

Via Investor's Business Daily

Topics Stocks

Overbought, Overextended - What's The Buzz In S&P 500 Now? ↗

February 14, 2024

Here are the red flags you need to be aware of in this current market and the directional bias for the long-term, swing and immediate term.

Via Talk Markets

Topics Stocks

3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗

February 08, 2024

These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.

Via InvestorPlace

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

Via Investor's Business Daily

Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

February 05, 2024

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) shares fell sharply during today’s pre-market trading.

Via Benzinga

Topics Stocks

3 Healthcare Stocks at 52-Week Lows: Buy or Bye? ↗

January 26, 2024

Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.

Via InvestorPlace

Biotech Playbook: Small Caps Show Momentum Peaking During ↗

January 15, 2024

The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market.

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.